Abstract
We recently encountered a destructive case of tophaceous gout in a 57-year-old patient. Despite perfect therapy compliance, the patient failed in the conventional urate-lowering treatment, accounting for the ongoing urate retention and accumulation with progressive tophaceous bulky disease. Application of an experimental scheme of uricolytical therapy on this patient was able to reduce bulky disease significantly. In modern medicine, potent urate-debulking medication with urate oxidase (uricase) derivatives is at our disposal, and it is a challenge for rheumatologists to install the right strategy including innovative approaches with potent uricolytic therapy on the right patient at the right time.
Similar content being viewed by others
References
Fam AG (1999) Hyperuricemia and gout. In: Rakel RE (ed) Conn's current therapy, 51st edn. Saunders, Philadelphia, pp 561–566
Emmerson BT (1996) The management of gout. N Engl J Med 334:445–451
Terkeltaub RA (2003) Gout. N Engl J Med 349(17):1647–1655
Bieber JD, Terkeltaub RA (2004) Gout; on the brink of novel therapeutic options for an ancient disease. Arthritis Rheum 50(8):2400–2414
Perez-Ruiz F, Alonzo-Ruiz A, Calabozo M et al (1998) Efficacy of allopurinol and benzbromarone for the control of hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 57:545–549
Jansen TLThA, Reinders MK, Van Roon EN, Brouwers JRBJ (2004) Benzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”? Clin Exp Rheumatol 22(5):651
Tausche AK, Richter K, Grässler A, Hänsel S, Roch B, Schröder HE (2004) Severe gouty arthritis refractory to anti-inflammatory drugs: treatment with anti-tumour necrosis factor alpha as a new therapeutic option. Ann Rheum Dis 63:1351–1352
Choi HK, Atkinson K, Karlson EW, Willett W, Curhan G (2004) Purine-rich foods, dairy and protein intake, and the risk of gout in men. N Engl J Med 350(11):1093–1103
Davidson MB, Thakkar S, Hix JK et al (2004) Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 116:546–555
Rozenberg S, Roch B, Dorent R, Koeger AC, Borget Wrona N, Bourgeois P (1995) Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases. Rev Rhum (Engl Ed) 62(5):392–394
Loeb JN (1972) The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15:189–192
Seegmiller JE (1965) The acute attack of gouty arthritis. Arthritis Rheum 8:714–723
Li-Yu J, Clayburne G, Sieck M et al (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28:577–580
Mc Carty DJ (1994) Gout without hyperuricemia. JAMA 271:302–303
Ferraz MB, O'Brien B (1995) A cost effective analysis of urate lowering drugs in non-tophaceous recurrent gouty arthritis. J Rheumatol 22:908–914
Author information
Authors and Affiliations
Corresponding author
Additional information
The presented case has been published before in a local Dutch mailing for rheumatologists.
Rights and permissions
About this article
Cite this article
Moolenburgh, J.D., Reinders, M.K. & Jansen, T.L.T.A. Rasburicase treatment in severe tophaceous gout: a novel therapeutic option. Clin Rheumatol 25, 749–752 (2006). https://doi.org/10.1007/s10067-005-0043-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0043-y